Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Mar. Drugs 2013, 11(10), 4035-4049; doi:10.3390/md11104035
Article

Identification of Two Novel Anti-Fibrotic Benzopyran Compounds Produced by Engineered Strains Derived from Streptomyces xiamenensis M1-94P that Originated from Deep-Sea Sediments

1
, 2
, 2
, 3
, 4
, 1
, 5
, 1
 and 1,*
Received: 17 August 2013; in revised form: 16 September 2013 / Accepted: 26 September 2013 / Published: 22 October 2013
(This article belongs to the Special Issue Advances and New Perspectives in Marine Biotechnology)
View Full-Text   |   Download PDF [691 KB, uploaded 22 October 2013]   |   Browse Figures
Abstract: The benzopyran compound obtained by cultivating a mangrove-derived strain, Streptomyces xiamenensis strain 318, shows multiple biological effects, including anti-fibrotic and anti-hypertrophic scar properties. To increase the diversity in the structures of the available benzopyrans, by means of biosynthesis, the strain was screened for spontaneous rifampicin resistance (Rif), and a mutated rpsL gene to confer streptomycin resistance (Str), was introduced into the S. xiamenensis strain M1-94P that originated from deep-sea sediments. Two new benzopyran derivatives, named xiamenmycin C (1) and D (2), were isolated from the crude extracts of a selected Str-Rif double mutant (M6) of M1-94P. The structures of 1 and 2 were identified by analyzing extensive spectroscopic data. Compounds 1 and 2 both inhibit the proliferation of human lung fibroblasts (WI26), and 1 exhibits better anti-fibrotic activity than xiamenmycin. Our study presents the novel bioactive compounds isolated from S. xiamenensis mutant strain M6 constructed by ribosome engineering, which could be a useful approach in the discovery of new anti-fibrotic compounds.
Keywords: Streptomyces xiamenensis; ribosome engineering; benzopyran; anti-fibrosis Streptomyces xiamenensis; ribosome engineering; benzopyran; anti-fibrosis
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

You, Z.-Y.; Wang, Y.-H.; Zhang, Z.-G.; Xu, M.-J.; Xie, S.-J.; Han, T.-S.; Feng, L.; Li, X.-G.; Xu, J. Identification of Two Novel Anti-Fibrotic Benzopyran Compounds Produced by Engineered Strains Derived from Streptomyces xiamenensis M1-94P that Originated from Deep-Sea Sediments. Mar. Drugs 2013, 11, 4035-4049.

AMA Style

You Z-Y, Wang Y-H, Zhang Z-G, Xu M-J, Xie S-J, Han T-S, Feng L, Li X-G, Xu J. Identification of Two Novel Anti-Fibrotic Benzopyran Compounds Produced by Engineered Strains Derived from Streptomyces xiamenensis M1-94P that Originated from Deep-Sea Sediments. Marine Drugs. 2013; 11(10):4035-4049.

Chicago/Turabian Style

You, Zhong-Yuan; Wang, Ya-Hui; Zhang, Zhi-Gang; Xu, Min-Juan; Xie, Shu-Jie; Han, Tie-Sheng; Feng, Lei; Li, Xue-Gong; Xu, Jun. 2013. "Identification of Two Novel Anti-Fibrotic Benzopyran Compounds Produced by Engineered Strains Derived from Streptomyces xiamenensis M1-94P that Originated from Deep-Sea Sediments." Mar. Drugs 11, no. 10: 4035-4049.



Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert